Search results
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
HEMOCLOT DTI 1 (Direct Thrombin Inhibitors)
Quantitative measurement of dabigatran, and anti-thrombin activities in plasma.
BIOPHEN DTI (Direct Thrombin Inhibitors)
Assay proposed for the measurement of anti-IIa activity in research applications.
Factor XIII Deficient Plasma
For any in vitro protocol or research study where a source of human FXIII deficient plasma is required.
Factor X Deficient Plasma
Measurement of factor X (FX or stuart factor) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FX deficient plasma is required
Factor XII Deficient Plasma
Measurement of factor XII (FXII or factor hageman) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent).For any in vitro protocol or research study where a source of human FXII deficient plasma is required.
Thrombin, bovine, purified
Recommended for all research protocols where a source of highly purified and characterized thrombin is necessary, and studies on anti-thrombin activities.
Thrombin, bovine, purified
Recommended for all research protocols where a source of highly purified and characterized thrombin is necessary, and studies on anti-thrombin activities.
Thrombin, bovine, purified
Recommended for all research protocols where a source of highly purified and characterized thrombin is necessary, and studies on anti-thrombin activities.